InterventionsHumans

Cardiorenal Benefits of SGLT2 Inhibitors in HFrEF Patients with ESRD Requiring Dialysis

AHA Scientific Sessions 2025 Abstract

The paper

Weiss A, Evenhuis B, Ahmed T et al.

AHA Scientific Sessions 2025 Abstract · 3 Nov 2025

Presented at AHA Scientific Sessions 2025 · Abstract 4370890

doi.org/10.1161/circ.152.suppl_3.4370890

GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Diabetes, Obesity & Metabolism · 4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Clinical Journal of the American Society of Nephrology · 4 Oct 2026
SGLT2 inhibitors raise genital but not urinary infection risk
Clinical Pharmacology and Therapeutics · 4 Oct 2026
Early physical therapy links to lower mortality in heart failure
Journal of Clinical Medicine · 4 Oct 2026